252P - Expression of Ribophorine II (RPN2) is a new prognostic factor in human gastric adenocarcinoma.

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Gastric Cancer
Translational Research
Presenter Daisuke Fujimoto
Citation Annals of Oncology (2016) 27 (suppl_9): ix68-ix85. 10.1093/annonc/mdw582
Authors D. Fujimoto, T. Goi, H. Kurebayashi, S. Kato, M. Morikawa, K. Koneri, M. Murakami, Y. Hirono
  • Department Of First Surgery, University of Fukui Hospital, 9101193 - Fukui/JP



The increased invasiveness of gastric adenocarcinoma is important for progression and metastasis. In recent molecular biological studies, Ribophorine II(RPN2) induces epithelial-mesenchymal transition and metastatic activity in highly metastatic breast cancer cells. However, no studies have evaluated the relationship between RPN2 expression, ability of cancer to invade/metastasis, and patient prognosis in gastric adenocarcinoma. Accordingly, we have examined these factors.


Immunohistochemical staining was performed to detect RPN2 in the primary lesion and adjacent normal gastric mucosa of 242 gastric adenocarcinoma patients who underwent resection surgery. Additionally, we conducted clinicopathologic examinations and analyzed patient prognoses with the Kaplan-Meier method. Further, multivariate analysis was conducted using a cox-hazard model.


RPN2 expression was observed in 119 of 242 cases of gastric adenocarcinoma patients. RPN2 expression was associated with a higher incidence of depth of wall invasion, lymphnode metastasis, lymphatic invasion, venous invasion, peritoneal dissemination, and histopathological stage. In Stage II and III curative resection cases, where recurrence is the most serious problem, cases that expressed RPN2 had a significantly lower 5-year survival rate and higher recurrence rate compared to these cases with no RPN2 expression. In the multivariate analysis for prognosis, RPN2 expression was found to be an independent factor.


RPN2 expression correlates with gastric adenocarcinoma cell invasion and could be one of the new prognostic factors in human gastric adenocarcinoma.

Clinical trial indentification

Legal entity responsible for the study



JSPS KAKENHI Grant number 26861065


All authors have declared no conflicts of interest.